TYK Medicines' Cancer Drug Accepted for Mini Oral Presentation at Medical Conference
MT Newswires Live
Aug 14
TYK Medicines (HKG:2410) said the results from a mid-stage study of its experimental cancer drug TY-9591 were accepted for mini oral presentation at the World Conference on Lung Cancer, according to a Thursday filing with the Hong Kong bourse.
The company will present interim results from the Esaona phase 2 study in subjects with EGFR-mutant non-small cell lung cancer.
The study is examining how well TY-9591, or asandeutertinib, works when compared to osimertinib in previously untreated patients.
Based on data available as of Feb. 28, asandeutertinib had a superior objective response rate of 84.7% versus osimertinib's 75.2% in patients whose cancer had spread to the brain, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.